CTLA4 and metastatic melanoma: The safety of the combination in clinical practice was reported in the CHARLI trial, a phase I/II study of the effect of denosumab with nivolumab (an anti-PD-1), with or without ipilimumab (anti-CTLA4), in patients with metastatic melanoma, which showed that the combination is safe and with at least interesting response rates [42].